Jerome H. Chin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jerome H. Chin has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Willy Ssengooba
Department of Medical Microbiology, Makerere University, Kampala, Uganda
5 shared publications - Amy C. Lee
Palo Alto Medical Foundation
2 shared publications Ana-Claire Meyer
From the Palo Alto Medical Foundation (A.C.L.), Mountain View, CA; University of California (J.C.), Berkeley; International Neurologic & Psychiatric Epidemiology Program (G.L.B.), Michigan State University, East Lansing; University of Zambia (G.L.B.), Lusaka; Epilepsy Care Team and Consultant (G.L.B.), Chikankata Hospital, Mazabuka, Zambia; Mayo Clinic (J.B.), Rochester, MN; University of California (A.-C.M.), San Francisco; and Kenya Medical Research Institute (A.-C.M.), Kisumu, Kenya
2 shared publicationsAska Twinobuhungiro
Department of Medical Services, Uganda Defense Forces, Uganda; Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda
2 shared publicationsGretchen L. Birbeck
From the Palo Alto Medical Foundation (A.C.L.), Mountain View, CA; University of California (J.C.), Berkeley; International Neurologic & Psychiatric Epidemiology Program (G.L.B.), Michigan State University, East Lansing; University of Zambia (G.L.B.), Lusaka; Epilepsy Care Team and Consultant (G.L.B.), Chikankata Hospital, Mazabuka, Zambia; Mayo Clinic (J.B.), Rochester, MN; University of California (A.-C.M.), San Francisco; and Kenya Medical Research Institute (A.-C.M.), Kisumu, Kenya
2 shared publications- Jacob Pellinen
Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA
2 shared publications
Latest Publications
- Open Access
- 10 December 2020
- Published by Springer Nature in BMC Neurology
- Vol. 20 (1) , 1-5
Autoimmune glial fibrillary acidic protein astrocytopathy manifesting as subacute meningoencephalitis with descending myelitis: a case report
Background: Glial fibrillary acidic protein (GFAP) autoimmune astrocytopathy is characterized by GFAP autoantibody positive encephalitis, meningoencephalitis or meningoencephalomyelitis. The initial clinical presentation may be similar to central nervous system infections making early diagnosis challenging. Case presentation: A Chinese female patient presented with subacute meningitis with symptoms of headache, vomiting, and fever. Cerebrospinal fluid (CSF) analysis showed monocytic pleocytosis, elevated protein level, low glucose level, and negative basic microbiological studies including Xpert MTB/RIF. Brain magnetic resonance imaging (MRI) showed bilateral cerebral cortical and white matter hyperintensities on FLAIR sequences. The patient was diagnosed with possible tuberculous meningitis and started on anti-tuberculosis therapy (ATT). Three months later, the patient developed cervical myelopathy and encephalopathy with persistent CSF pleocytosis. Five months later, tissue-based and cell-based assays demonstrated GFAP antibodies in blood and CSF. Her symptoms improved with repeated administration of intravenous immunoglobulin (IVIG) and corticosteroids. One-and-a-half -year follow-up showed neither clinical progression nor relapses. Conclusions: Anti-GFAP astrocytopathy should be included in the differential diagnosis of patients who present with subacute meningitis with negative microbiological studies and a progressive clinical course including encephalitis and/or myelitis.
- 10 December 2020
- Published by Springer Nature in BMC Neurology
- Vol. 20 (1) , 1-5
Open AccessAutoimmune glial fibrillary acidic protein astrocytopathy manifesting as subacute meningoencephalitis with descending myelitis: a case report
Background: Glial fibrillary acidic protein (GFAP) autoimmune astrocytopathy is characterized by GFAP autoantibody positive encephalitis, meningoencephalitis or meningoencephalomyelitis. The initial clinical presentation may be similar to central nervous system infections making early diagnosis challenging. Case presentation: A Chinese female patient presented with subacute meningitis with symptoms of headache, vomiting, and fever. Cerebrospinal fluid (CSF) analysis showed monocytic pleocytosis, elevated protein level, low glucose level, and negative basic microbiological studies including Xpert MTB/RIF. Brain magnetic resonance imaging (MRI) showed bilateral cerebral cortical and white matter hyperintensities on FLAIR sequences. The patient was diagnosed with possible tuberculous meningitis and started on anti-tuberculosis therapy (ATT). Three months later, the patient developed cervical myelopathy and encephalopathy with persistent CSF pleocytosis. Five months later, tissue-based and cell-based assays demonstrated GFAP antibodies in blood and CSF. Her symptoms improved with repeated administration of intravenous immunoglobulin (IVIG) and corticosteroids. One-and-a-half -year follow-up showed neither clinical progression nor relapses. Conclusions: Anti-GFAP astrocytopathy should be included in the differential diagnosis of patients who present with subacute meningitis with negative microbiological studies and a progressive clinical course including encephalitis and/or myelitis.
- Open Access
- 1 December 2020
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 22, 100882
Severe headache as the sole presenting symptom of COVID-19 pneumonia: A case report
- 1 December 2020
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 22, 100882
Open AccessSevere headache as the sole presenting symptom of COVID-19 pneumonia: A case report
- Open Access
- 1 May 2020
- Published by Elsevier in Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
- Vol. 19, 100145
Medical management of acute loss of vision in tuberculous meningitis: A case report
- 1 May 2020
- Published by Elsevier in Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
- Vol. 19, 100145
Open AccessMedical management of acute loss of vision in tuberculous meningitis: A case report
- 17 April 2020
- Published by Elsevier
- p. 17-24
Immunopathology of Mycobacterium tuberculosis complex
- 1 January 2020
- Published by Elsevier
- p. 53-66
Identification of Mycobacterium tuberculosis drug resistance
- 1 January 2020
- Published by Elsevier
- p. 53-66
Identification of Mycobacterium tuberculosis drug resistance
- 1 January 2020
- Published by Elsevier
- p. 37-51
Laboratory methods for detecting tuberculosis and tuberculous meningitis
- 1 January 2020
- Published by Elsevier
- p. 37-51
Laboratory methods for detecting tuberculosis and tuberculous meningitis
- 1 August 2019
- Published by Georg Thieme Verlag KG in Seminars in Neurology
- Vol. 39 (04) , 456-461
Neurotuberculosis: A Clinical Review
In September 2018, the United Nations General Assembly held the first ever meeting to discuss the global epidemic of tuberculosis (TB) and adopted a political declaration titled “United to end tuberculosis: an urgent global response to a global epidemic.” The timing of the meeting was prescient but overdue since Mycobacterium tuberculosis surpassed the human immunodeficiency virus as the world's leading infectious killer in 2014. Infection of the central nervous system by Mycobacterium tuberculosis, herein referred to as neurotuberculosis, is the most feared and dangerous form of tuberculosis, requiring a high level of suspicion and clinical experience for prompt diagnosis and treatment. Neurologists, infectious disease specialists, orthopedic surgeons, neurosurgeons, and hospitalists in all countries need to recognize the spectrum of neurotuberculosis and be able to integrate clinical information, laboratory data, and radiological findings to make a diagnosis with or without microbiological confirmation.
- 1 August 2019
- Published by Georg Thieme Verlag KG in Seminars in Neurology
- Vol. 39 (04) , 456-461
Neurotuberculosis: A Clinical Review
In September 2018, the United Nations General Assembly held the first ever meeting to discuss the global epidemic of tuberculosis (TB) and adopted a political declaration titled “United to end tuberculosis: an urgent global response to a global epidemic.” The timing of the meeting was prescient but overdue since Mycobacterium tuberculosis surpassed the human immunodeficiency virus as the world's leading infectious killer in 2014. Infection of the central nervous system by Mycobacterium tuberculosis, herein referred to as neurotuberculosis, is the most feared and dangerous form of tuberculosis, requiring a high level of suspicion and clinical experience for prompt diagnosis and treatment. Neurologists, infectious disease specialists, orthopedic surgeons, neurosurgeons, and hospitalists in all countries need to recognize the spectrum of neurotuberculosis and be able to integrate clinical information, laboratory data, and radiological findings to make a diagnosis with or without microbiological confirmation.
- 1 June 2019
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 57 (6)
Xpert MTB/RIF Ultra for Detection of Mycobacterium tuberculosis in Cerebrospinal Fluid
- 1 June 2019
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 57 (6)
Xpert MTB/RIF Ultra for Detection of Mycobacterium tuberculosis in Cerebrospinal Fluid
- 1 April 2019
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 9 (2) , 152-154
Tuberculous meningitis
Tuberculosis (TB) surpassed HIV as the world9s leading infectious cause of death in 2014. Although billions of dollars have been invested to reduce the global burden of pulmonary TB, tuberculous meningitis (TBM), the most lethal manifestation of the disease, has remained largely neglected with a paucity of evidence-based guidelines. Research is urgently needed to obtain reliable estimates of the global incidence of TBM, develop high performance technologies to detect TBM in CSF, and evaluate drug regimens with greater penetration of the CNS.
- 1 April 2019
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 9 (2) , 152-154
Tuberculous meningitis
Tuberculosis (TB) surpassed HIV as the world9s leading infectious cause of death in 2014. Although billions of dollars have been invested to reduce the global burden of pulmonary TB, tuberculous meningitis (TBM), the most lethal manifestation of the disease, has remained largely neglected with a paucity of evidence-based guidelines. Research is urgently needed to obtain reliable estimates of the global incidence of TBM, develop high performance technologies to detect TBM in CSF, and evaluate drug regimens with greater penetration of the CNS.
- Open Access
- 1 February 2019
- Published by Elsevier in Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
- Vol. 14, 16-18
Xpert MTB/RIF Ultra: Optimal procedures for the detection of Mycobacterium tuberculosis in cerebrospinal fluid
- 1 February 2019
- Published by Elsevier in Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
- Vol. 14, 16-18
Open AccessXpert MTB/RIF Ultra: Optimal procedures for the detection of Mycobacterium tuberculosis in cerebrospinal fluid